case_images: PMC11296372_01
case_images: Brain contrast-enhanced magnetic resonance imaging (MRI) scans show brain metastases before and after anlotinib and T-DXd therapy. (A) brain metastases before anlotinib and T-DXd therapy; (B) partial response in brain metastases after anlotinib and T-DXd treatment.
case_images: IJWH-16-1277-g0001.jpg
case_images: PMC11296372_01_IJWH-16-1277-g0001.jpg
case_images: f0001
case_images: On September 13, 2022, brain MRI indicated new metastatic lesion in the left basal ganglia area and enlargement of lesions in the left frontal lobe and right parietal lobe (Figure 1A), and chest CT showed a reduction in the size of lung lesions (Figure 2A). T-DXd, the patient achieved partial response of BMs (Figure 1B) and lung metastases (Figure 2B), with tolerable side effects including grade 2 thrombocytopenia and grade 2 leukopenia.
case_images: Chest and abdominal enhanced computed tomography(CT) scans show lung metastases before and after anlotinib and T-DXd therapy. (A) lung metastases before anlotinib and T-DXd therapy; (B) partial response in lung metastases after anlotinib and T-DXd treatment.
case_images: IJWH-16-1277-g0002.jpg
case_images: PMC11296372_01_IJWH-16-1277-g0002.jpg
case_images: f0002
case_images: On September 13, 2022, brain MRI indicated new metastatic lesion in the left basal ganglia area and enlargement of lesions in the left frontal lobe and right parietal lobe (Figure 1A), and chest CT showed a reduction in the size of lung lesions (Figure 2A). T-DXd, the patient achieved partial response of BMs (Figure 1B) and lung metastases (Figure 2B), with tolerable side effects including grade 2 thrombocytopenia and grade 2 leukopenia.
case_images: Timeline of the clinical course in this patient.
case_images: IJWH-16-1277-g0003.jpg
case_images: PMC11296372_01_IJWH-16-1277-g0003.jpg
case_images: f0003
case_images: Figure 3 outlines the medical history of this patient.